Patients who received 1 of 6 dosing regimens of evolocumab in the parent studies and received evolocumab + SOC in OSLER had persistent LDL-C reductions ( mean reduction , 50.4 % [ SE , 0.8 % ] at the end of the parent study versus 52.1 % [ SE , 1.0 % ] at 52 weeks ; P = 0.31 ) .